Renal carcinoma
Conditions
Interventions
Group one:Unassisted zero-ischemic enucleation
Sponsors
The Fourth Affiliated Hospital, Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. The informed consent has been fully understood and signed voluntarily; age between from 18 years old to 80 years old; 2. TNM stage T1a or T1b of kidney cancer according to the 2017 8th edition of AJCC; 3. Estimated survival >=12 months; Meet the requirements of follow-up for 12 months; 4. Be willing and able to comply with the visit, treatment, laboratory examination and other study procedures of the study plan; 5. Adequate organ function; 6. Improved ABC score <= 2b.
Exclusion criteria
Exclusion criteria: 1. Accompanied by serious active infection or serious diseases of the heart, liver, kidney and hematopoietic system; And others whose physical condition is not suitable for the relevant test (as determined by the investigator); 2. The patient has no measurable or evaluable lesions; 3. Poor compliance; Easy to lose visitors; 4. History of organ transplantation or need long-term adrenocorticosteroid therapy; Patients with hypothyroidism, adrenal or pituitary function that can be controlled by hormone replacement therapy alone, type I diabetes mellitus, psoriasis or vitiligo that do not require systematic treatment can participate in this study; 5. There are active infections requiring systematic treatment, human immunodeficiency virus (HIV) infection (known to be HIV antibody positive), active HBV or HCV infection (HBsAg positive, or HBcAb positive but HBsAg negative, additional DNA quantification is required. Those whose results do not exceed the upper limit of normal value in the laboratory of the research center can participate in this study; Previous HCV infection screening period HCV? If the RNA test result is negative, you can participate in this study); 6. Patients who cannot tolerate laparoscopic surgery, have a history of kidney surgery or any inflammatory kidney surgery, have renal cancer associated with the urinary collecting system, and have other kidney diseases (including kidney stones and glomerulonephritis); 7. Subject has a history or current evidence of any disease, treatment, or laboratory abnormality that, in the Investigator's judgment, may confound the study results, interfere with subjects' participation in the full study, or is not in their best interest to participate in the study; 8. Vulnerable groups include but are not limited to persons with mental illness, critically ill patients, pregnant women, minors, persons with cognitive disabilities, students of researchers, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival;Tumor free survival;Progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Modified ABC score;Tumor volume;Blood loss;Creatinine;Glomerular filtration rate; | — |
Countries
China
Contacts
Public ContactZhen Yichun
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Outcome results
None listed